Principal Scientist
Bristol-Myers Squibb Company
Fizal has over 36 years of experience as a researcher in the Pharmaceutical industry, working in Forensic Toxicology, Analytical Chemistry, Pharmacokinetics, Pharmacodynamics and most recently Analytical Biochemistry/ Immunochemistry. Fizal is skilled in a variety of analytical instruments and techniques, and employed his experience and creativity to successfully supported development of many novel pharmaceutical compounds during his career in the industry. In 2006 his Abstract, “Development and Validation of a Novel Method for Quantitation of Phosphorylated Heat Shock Protein 27 in Cells Isolated from Human Whole Blood” won the AAPS award for excellence in ligand binding assays. In 2015 his abstract, “Performance Comparison of Multiple Ultra High Sensitivity Immunoassay Platforms Using the Same IL-31 Antibodies” again won the AAPS award for excellence in ligand binding assays. In 2018 Fizal attained his PhD in Cell and Molecular Biology From St Josephs University (formarly University of The Sciences, Philadelphia). Fizal served on AAPS BSSC as the student liaison for NBC and AM where he worked on developing the Co-moderator program to a higher level and worked on a process for placing students in AAPS Biotec sessions. Fizal also served as AAPS abstract reviewer for many years and was the Track 3 Chair in 2022. Fizal also serves on CDISC Lab team supporting development of controlled terminology for biomarkers and serves on the board of directors on NOVA bucks county.